Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Auxilium Pharmaceuticals, Inc.    AUXL   US05334D1072

SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201120122013201420152016
Sales264395401401505647
Operating income (EBITDA)-25,210456,017,5125160
Operating profit (EBIT)-33,285,545,117,5125160
Pre-Tax Profit (EBT)-32,985,9-96,4---
Net income-32,985,9-18,1-16371,5112
EPS ( $)-0,691,74-0,37-3,251,402,16
Dividend per Share ( $)------
Yield------
Announcement Date02/23/2012
12:00pm
02/26/2013
12:00pm
02/28/2014
11:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201120122013201420152016
Debt--246479364177
Finance154157----
Operating income (EBITDA)-25,210456,017,5125160
Leverage
(Debt/EBITDA)
--4,39x27,3x2,92x1,11x
Capital Expenditure6,648,7610,4---
Book Value Per Share (BVPS)1,75 $4,06 $5,07 $---
Cash Flow per Share0,64 $-0,05 $-0,24 $---
Announcement Date02/23/2012
12:00pm
02/26/2013
12:00pm
02/28/2014
11:30am
---
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2014e 2015e
Capitalization 1 850 M$ -
Entreprise Value (EV) 2 328 M$ 2 214 M$
Valuation 2014e 2015e
PER (Price / EPS) 26,1x
Capitalization / Revenue 4,61x 3,66x
EV / Revenue 5,81x 4,38x
EV / EBITDA 133x 17,7x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2014e 2015e
Operating Margin (EBIT / Sales) 4,37% 24,7%
operating Leverage (Delta EBIT / Delta Sales) - 23,6x
Net Margin (Net Profit / Revenue) -40,7% 14,1%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2014e 2015e
CAPEX / Sales   - -
Cash Flow / Sales (Taux d'autofinancement) - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 27,3x 2,92x
Price Earning Ratio
EPS & Dividend